Aggressive Systemic Mastocytosis
Aggressive Systemic Mastocytosis is a rare disorder driven by abnormal mast cell accumulation in multiple organs, often associated with KIT mutations and organ dysfunction.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Aggressive Systemic Mastocytosis in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| KIT |
|
Defined at the solid tumor level and applicable to Aggressive Systemic Mastocytosis and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Aggressive Systemic Mastocytosis. Select a therapy to view the specific approval and eligible tests.
KIT (D816V)